VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
Gilead Sciences, Inc. vs Stevanato Group S.p.A.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisStevanato Group S.p.A.
STVN · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Stevanato Group S.p.A.'s moat claims, evidence, and risks.
View STVN analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 59 / 100 for Stevanato Group S.p.A.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Stevanato Group S.p.A. has 3 segments (46.3% in Other Containment and Delivery Solutions).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Weak.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Stevanato Group S.p.A. has 8 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Stevanato Group S.p.A.
Other Containment and Delivery Solutions
Standard primary packaging and related services for injectable drugs and diagnostics
Global
Pharmaceutical, biotechnology, diagnostics and life sciences companies; fill-finish CMOs
Primary packaging/component manufacturer and contract manufacturing partner
46.3%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Stevanato Group S.p.A. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Stevanato Group S.p.A. segments
Full profile >High-Value Solutions
Oligopoly
Other Containment and Delivery Solutions
Competitive
Engineering
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.